Global Depression Drugs

Depression Drugs Comprehensive Study by Type (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Others), Application (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others), Distribution Channel (Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2028

Depression Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Depression Drugs
Depression refers to a group of mental health issues marked by a lack of positive emotion, a depressed mood, and a variety of cognitive, physical, emotional, and behavioral symptoms. Depression can be caused by a variety of causes, including genetics, stress, and brain chemistry. Depression medications aid in the treatment of depression by balancing numerous hormones and chemicals in the brain. The market is driven by an increase in the prevalence of depression, an increase in the geriatric population, and the discovery of novel approaches for the creation of medications with fewer adverse effects. Furthermore, rising knowledge of the illness condition and essential therapeutic demands, as well as an increase in the number of people suffering from stress, could propel the market forward. Over the last few years, advances in the neuroscience of depression have opened up new antidepressant treatment options. In addition, market participants are increasingly focusing on the development of novel non-pharmacologic and pharmacologic therapies in the present depression medicine market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Depression Drugs is a fragmented market due to the presence of various players. The many changes within the industry underscore the fact that there is an increasingly more competitive landscape. The players are focusing on planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Depression Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbiVe Inc. (United States), Janssen Pharmaceuticals (Belgium), AstraZeneca (United Kingdom), Eli Lilly and Company(United States), GlaxoSmithKline PLC (United Kingdom), Johnson & Johnson(United States), H. Lundbeck AS (Denmark), Merck & Co. Inc.(United States), Pfizer Inc.(United States), Sanofi (France), Sun Pharmaceuticals Pvt. Ltd (India) and Dr. Reddy's Laboratories (India) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Depression Drugs market by Type (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors and Others), Application (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Others) and Region.



On the basis of geography, the market of Depression Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Retail Pharmacies will boost the Depression Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The emergence of Novel Biologics

Market Growth Drivers:
Increasing Number of Cases of Depression Around the World and Increasing Awareness About Depression

Challenges:
Stringent Regulatory Factors

Restraints:
Side Effects Related to Drugs

Opportunities:
Growing Research and Development Activities and Growing Drug Development Activities

Market Leaders and their expansionary development strategies
In November 2023, AbbVie Inc. and ImmunoGen, Inc. announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space.
In August 2020 – Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior


Key Target Audience
Drug Manufacturers and Suppliers, Academic Research Institutes, Hospitals and Clinics, Research and Development (R&D) Companies, Governmental Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist And Reuptake Inhibitors
  • Others
By Application
  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cases of Depression Around the World
      • 3.2.2. Increasing Awareness About Depression
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors
    • 3.4. Market Trends
      • 3.4.1. The emergence of Novel Biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Depression Drugs, by Type, Application, Distribution Channel and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Depression Drugs (Value)
      • 5.2.1. Global Depression Drugs by: Type (Value)
        • 5.2.1.1. Tricyclic Antidepressants
        • 5.2.1.2. Selective Serotonin Reuptake Inhibitors
        • 5.2.1.3. Serotonin-Norepinephrine Reuptake Inhibitors
        • 5.2.1.4. Monoamine Oxidase Inhibitors
        • 5.2.1.5. Serotonin Antagonist And Reuptake Inhibitors
        • 5.2.1.6. Others
      • 5.2.2. Global Depression Drugs by: Application (Value)
        • 5.2.2.1. Major Depressive Disorder
        • 5.2.2.2. Obsessive-Compulsive Disorder
        • 5.2.2.3. Generalized Anxiety Disorder
        • 5.2.2.4. Panic Disorder
        • 5.2.2.5. Others
      • 5.2.3. Global Depression Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Online Pharmacies
      • 5.2.4. Global Depression Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Depression Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbiVe Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Pharmaceuticals (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. H. Lundbeck AS (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co. Inc.(United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc.(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sun Pharmaceuticals Pvt. Ltd (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Dr. Reddy's Laboratories (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Depression Drugs Sale, by Type, Application, Distribution Channel and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Depression Drugs (Value)
      • 7.2.1. Global Depression Drugs by: Type (Value)
        • 7.2.1.1. Tricyclic Antidepressants
        • 7.2.1.2. Selective Serotonin Reuptake Inhibitors
        • 7.2.1.3. Serotonin-Norepinephrine Reuptake Inhibitors
        • 7.2.1.4. Monoamine Oxidase Inhibitors
        • 7.2.1.5. Serotonin Antagonist And Reuptake Inhibitors
        • 7.2.1.6. Others
      • 7.2.2. Global Depression Drugs by: Application (Value)
        • 7.2.2.1. Major Depressive Disorder
        • 7.2.2.2. Obsessive-Compulsive Disorder
        • 7.2.2.3. Generalized Anxiety Disorder
        • 7.2.2.4. Panic Disorder
        • 7.2.2.5. Others
      • 7.2.3. Global Depression Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Online Pharmacies
      • 7.2.4. Global Depression Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Depression Drugs: by Type(USD Million)
  • Table 2. Depression Drugs Tricyclic Antidepressants , by Region USD Million (2017-2022)
  • Table 3. Depression Drugs Selective Serotonin Reuptake Inhibitors , by Region USD Million (2017-2022)
  • Table 4. Depression Drugs Serotonin-Norepinephrine Reuptake Inhibitors , by Region USD Million (2017-2022)
  • Table 5. Depression Drugs Monoamine Oxidase Inhibitors , by Region USD Million (2017-2022)
  • Table 6. Depression Drugs Serotonin Antagonist And Reuptake Inhibitors , by Region USD Million (2017-2022)
  • Table 7. Depression Drugs Others , by Region USD Million (2017-2022)
  • Table 8. Depression Drugs: by Application(USD Million)
  • Table 9. Depression Drugs Major Depressive Disorder , by Region USD Million (2017-2022)
  • Table 10. Depression Drugs Obsessive-Compulsive Disorder , by Region USD Million (2017-2022)
  • Table 11. Depression Drugs Generalized Anxiety Disorder , by Region USD Million (2017-2022)
  • Table 12. Depression Drugs Panic Disorder , by Region USD Million (2017-2022)
  • Table 13. Depression Drugs Others , by Region USD Million (2017-2022)
  • Table 14. Depression Drugs: by Distribution Channel(USD Million)
  • Table 15. Depression Drugs Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 16. Depression Drugs Online Pharmacies , by Region USD Million (2017-2022)
  • Table 17. South America Depression Drugs, by Country USD Million (2017-2022)
  • Table 18. South America Depression Drugs, by Type USD Million (2017-2022)
  • Table 19. South America Depression Drugs, by Application USD Million (2017-2022)
  • Table 20. South America Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 21. Brazil Depression Drugs, by Type USD Million (2017-2022)
  • Table 22. Brazil Depression Drugs, by Application USD Million (2017-2022)
  • Table 23. Brazil Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 24. Argentina Depression Drugs, by Type USD Million (2017-2022)
  • Table 25. Argentina Depression Drugs, by Application USD Million (2017-2022)
  • Table 26. Argentina Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 27. Rest of South America Depression Drugs, by Type USD Million (2017-2022)
  • Table 28. Rest of South America Depression Drugs, by Application USD Million (2017-2022)
  • Table 29. Rest of South America Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 30. Asia Pacific Depression Drugs, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Depression Drugs, by Type USD Million (2017-2022)
  • Table 32. Asia Pacific Depression Drugs, by Application USD Million (2017-2022)
  • Table 33. Asia Pacific Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 34. China Depression Drugs, by Type USD Million (2017-2022)
  • Table 35. China Depression Drugs, by Application USD Million (2017-2022)
  • Table 36. China Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 37. Japan Depression Drugs, by Type USD Million (2017-2022)
  • Table 38. Japan Depression Drugs, by Application USD Million (2017-2022)
  • Table 39. Japan Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 40. India Depression Drugs, by Type USD Million (2017-2022)
  • Table 41. India Depression Drugs, by Application USD Million (2017-2022)
  • Table 42. India Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 43. South Korea Depression Drugs, by Type USD Million (2017-2022)
  • Table 44. South Korea Depression Drugs, by Application USD Million (2017-2022)
  • Table 45. South Korea Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 46. Taiwan Depression Drugs, by Type USD Million (2017-2022)
  • Table 47. Taiwan Depression Drugs, by Application USD Million (2017-2022)
  • Table 48. Taiwan Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 49. Australia Depression Drugs, by Type USD Million (2017-2022)
  • Table 50. Australia Depression Drugs, by Application USD Million (2017-2022)
  • Table 51. Australia Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Depression Drugs, by Type USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Depression Drugs, by Application USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 55. Europe Depression Drugs, by Country USD Million (2017-2022)
  • Table 56. Europe Depression Drugs, by Type USD Million (2017-2022)
  • Table 57. Europe Depression Drugs, by Application USD Million (2017-2022)
  • Table 58. Europe Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 59. Germany Depression Drugs, by Type USD Million (2017-2022)
  • Table 60. Germany Depression Drugs, by Application USD Million (2017-2022)
  • Table 61. Germany Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 62. France Depression Drugs, by Type USD Million (2017-2022)
  • Table 63. France Depression Drugs, by Application USD Million (2017-2022)
  • Table 64. France Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 65. Italy Depression Drugs, by Type USD Million (2017-2022)
  • Table 66. Italy Depression Drugs, by Application USD Million (2017-2022)
  • Table 67. Italy Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 68. United Kingdom Depression Drugs, by Type USD Million (2017-2022)
  • Table 69. United Kingdom Depression Drugs, by Application USD Million (2017-2022)
  • Table 70. United Kingdom Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 71. Netherlands Depression Drugs, by Type USD Million (2017-2022)
  • Table 72. Netherlands Depression Drugs, by Application USD Million (2017-2022)
  • Table 73. Netherlands Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 74. Rest of Europe Depression Drugs, by Type USD Million (2017-2022)
  • Table 75. Rest of Europe Depression Drugs, by Application USD Million (2017-2022)
  • Table 76. Rest of Europe Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 77. MEA Depression Drugs, by Country USD Million (2017-2022)
  • Table 78. MEA Depression Drugs, by Type USD Million (2017-2022)
  • Table 79. MEA Depression Drugs, by Application USD Million (2017-2022)
  • Table 80. MEA Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 81. Middle East Depression Drugs, by Type USD Million (2017-2022)
  • Table 82. Middle East Depression Drugs, by Application USD Million (2017-2022)
  • Table 83. Middle East Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 84. Africa Depression Drugs, by Type USD Million (2017-2022)
  • Table 85. Africa Depression Drugs, by Application USD Million (2017-2022)
  • Table 86. Africa Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 87. North America Depression Drugs, by Country USD Million (2017-2022)
  • Table 88. North America Depression Drugs, by Type USD Million (2017-2022)
  • Table 89. North America Depression Drugs, by Application USD Million (2017-2022)
  • Table 90. North America Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 91. United States Depression Drugs, by Type USD Million (2017-2022)
  • Table 92. United States Depression Drugs, by Application USD Million (2017-2022)
  • Table 93. United States Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 94. Canada Depression Drugs, by Type USD Million (2017-2022)
  • Table 95. Canada Depression Drugs, by Application USD Million (2017-2022)
  • Table 96. Canada Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 97. Mexico Depression Drugs, by Type USD Million (2017-2022)
  • Table 98. Mexico Depression Drugs, by Application USD Million (2017-2022)
  • Table 99. Mexico Depression Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Depression Drugs: by Type(USD Million)
  • Table 113. Depression Drugs Tricyclic Antidepressants , by Region USD Million (2023-2028)
  • Table 114. Depression Drugs Selective Serotonin Reuptake Inhibitors , by Region USD Million (2023-2028)
  • Table 115. Depression Drugs Serotonin-Norepinephrine Reuptake Inhibitors , by Region USD Million (2023-2028)
  • Table 116. Depression Drugs Monoamine Oxidase Inhibitors , by Region USD Million (2023-2028)
  • Table 117. Depression Drugs Serotonin Antagonist And Reuptake Inhibitors , by Region USD Million (2023-2028)
  • Table 118. Depression Drugs Others , by Region USD Million (2023-2028)
  • Table 119. Depression Drugs: by Application(USD Million)
  • Table 120. Depression Drugs Major Depressive Disorder , by Region USD Million (2023-2028)
  • Table 121. Depression Drugs Obsessive-Compulsive Disorder , by Region USD Million (2023-2028)
  • Table 122. Depression Drugs Generalized Anxiety Disorder , by Region USD Million (2023-2028)
  • Table 123. Depression Drugs Panic Disorder , by Region USD Million (2023-2028)
  • Table 124. Depression Drugs Others , by Region USD Million (2023-2028)
  • Table 125. Depression Drugs: by Distribution Channel(USD Million)
  • Table 126. Depression Drugs Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 127. Depression Drugs Online Pharmacies , by Region USD Million (2023-2028)
  • Table 128. South America Depression Drugs, by Country USD Million (2023-2028)
  • Table 129. South America Depression Drugs, by Type USD Million (2023-2028)
  • Table 130. South America Depression Drugs, by Application USD Million (2023-2028)
  • Table 131. South America Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 132. Brazil Depression Drugs, by Type USD Million (2023-2028)
  • Table 133. Brazil Depression Drugs, by Application USD Million (2023-2028)
  • Table 134. Brazil Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 135. Argentina Depression Drugs, by Type USD Million (2023-2028)
  • Table 136. Argentina Depression Drugs, by Application USD Million (2023-2028)
  • Table 137. Argentina Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 138. Rest of South America Depression Drugs, by Type USD Million (2023-2028)
  • Table 139. Rest of South America Depression Drugs, by Application USD Million (2023-2028)
  • Table 140. Rest of South America Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 141. Asia Pacific Depression Drugs, by Country USD Million (2023-2028)
  • Table 142. Asia Pacific Depression Drugs, by Type USD Million (2023-2028)
  • Table 143. Asia Pacific Depression Drugs, by Application USD Million (2023-2028)
  • Table 144. Asia Pacific Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 145. China Depression Drugs, by Type USD Million (2023-2028)
  • Table 146. China Depression Drugs, by Application USD Million (2023-2028)
  • Table 147. China Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 148. Japan Depression Drugs, by Type USD Million (2023-2028)
  • Table 149. Japan Depression Drugs, by Application USD Million (2023-2028)
  • Table 150. Japan Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 151. India Depression Drugs, by Type USD Million (2023-2028)
  • Table 152. India Depression Drugs, by Application USD Million (2023-2028)
  • Table 153. India Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 154. South Korea Depression Drugs, by Type USD Million (2023-2028)
  • Table 155. South Korea Depression Drugs, by Application USD Million (2023-2028)
  • Table 156. South Korea Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 157. Taiwan Depression Drugs, by Type USD Million (2023-2028)
  • Table 158. Taiwan Depression Drugs, by Application USD Million (2023-2028)
  • Table 159. Taiwan Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 160. Australia Depression Drugs, by Type USD Million (2023-2028)
  • Table 161. Australia Depression Drugs, by Application USD Million (2023-2028)
  • Table 162. Australia Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 163. Rest of Asia-Pacific Depression Drugs, by Type USD Million (2023-2028)
  • Table 164. Rest of Asia-Pacific Depression Drugs, by Application USD Million (2023-2028)
  • Table 165. Rest of Asia-Pacific Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 166. Europe Depression Drugs, by Country USD Million (2023-2028)
  • Table 167. Europe Depression Drugs, by Type USD Million (2023-2028)
  • Table 168. Europe Depression Drugs, by Application USD Million (2023-2028)
  • Table 169. Europe Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 170. Germany Depression Drugs, by Type USD Million (2023-2028)
  • Table 171. Germany Depression Drugs, by Application USD Million (2023-2028)
  • Table 172. Germany Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 173. France Depression Drugs, by Type USD Million (2023-2028)
  • Table 174. France Depression Drugs, by Application USD Million (2023-2028)
  • Table 175. France Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 176. Italy Depression Drugs, by Type USD Million (2023-2028)
  • Table 177. Italy Depression Drugs, by Application USD Million (2023-2028)
  • Table 178. Italy Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 179. United Kingdom Depression Drugs, by Type USD Million (2023-2028)
  • Table 180. United Kingdom Depression Drugs, by Application USD Million (2023-2028)
  • Table 181. United Kingdom Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 182. Netherlands Depression Drugs, by Type USD Million (2023-2028)
  • Table 183. Netherlands Depression Drugs, by Application USD Million (2023-2028)
  • Table 184. Netherlands Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 185. Rest of Europe Depression Drugs, by Type USD Million (2023-2028)
  • Table 186. Rest of Europe Depression Drugs, by Application USD Million (2023-2028)
  • Table 187. Rest of Europe Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 188. MEA Depression Drugs, by Country USD Million (2023-2028)
  • Table 189. MEA Depression Drugs, by Type USD Million (2023-2028)
  • Table 190. MEA Depression Drugs, by Application USD Million (2023-2028)
  • Table 191. MEA Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 192. Middle East Depression Drugs, by Type USD Million (2023-2028)
  • Table 193. Middle East Depression Drugs, by Application USD Million (2023-2028)
  • Table 194. Middle East Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 195. Africa Depression Drugs, by Type USD Million (2023-2028)
  • Table 196. Africa Depression Drugs, by Application USD Million (2023-2028)
  • Table 197. Africa Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 198. North America Depression Drugs, by Country USD Million (2023-2028)
  • Table 199. North America Depression Drugs, by Type USD Million (2023-2028)
  • Table 200. North America Depression Drugs, by Application USD Million (2023-2028)
  • Table 201. North America Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 202. United States Depression Drugs, by Type USD Million (2023-2028)
  • Table 203. United States Depression Drugs, by Application USD Million (2023-2028)
  • Table 204. United States Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 205. Canada Depression Drugs, by Type USD Million (2023-2028)
  • Table 206. Canada Depression Drugs, by Application USD Million (2023-2028)
  • Table 207. Canada Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 208. Mexico Depression Drugs, by Type USD Million (2023-2028)
  • Table 209. Mexico Depression Drugs, by Application USD Million (2023-2028)
  • Table 210. Mexico Depression Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Depression Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Depression Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Depression Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 7. South America Depression Drugs Share (%), by Country
  • Figure 8. Asia Pacific Depression Drugs Share (%), by Country
  • Figure 9. Europe Depression Drugs Share (%), by Country
  • Figure 10. MEA Depression Drugs Share (%), by Country
  • Figure 11. North America Depression Drugs Share (%), by Country
  • Figure 12. Global Depression Drugs share by Players 2022 (%)
  • Figure 13. Global Depression Drugs share by Players (Top 3) 2022(%)
  • Figure 14. Global Depression Drugs share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AbbiVe Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. AbbiVe Inc. (United States) Revenue: by Geography 2022
  • Figure 18. Janssen Pharmaceuticals (Belgium) Revenue, Net Income and Gross profit
  • Figure 19. Janssen Pharmaceuticals (Belgium) Revenue: by Geography 2022
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 22. Eli Lilly and Company(United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company(United States) Revenue: by Geography 2022
  • Figure 24. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 26. Johnson & Johnson(United States) Revenue, Net Income and Gross profit
  • Figure 27. Johnson & Johnson(United States) Revenue: by Geography 2022
  • Figure 28. H. Lundbeck AS (Denmark) Revenue, Net Income and Gross profit
  • Figure 29. H. Lundbeck AS (Denmark) Revenue: by Geography 2022
  • Figure 30. Merck & Co. Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co. Inc.(United States) Revenue: by Geography 2022
  • Figure 32. Pfizer Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc.(United States) Revenue: by Geography 2022
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2022
  • Figure 36. Sun Pharmaceuticals Pvt. Ltd (India) Revenue, Net Income and Gross profit
  • Figure 37. Sun Pharmaceuticals Pvt. Ltd (India) Revenue: by Geography 2022
  • Figure 38. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 39. Dr. Reddy's Laboratories (India) Revenue: by Geography 2022
  • Figure 40. Global Depression Drugs: by Type USD Million (2023-2028)
  • Figure 41. Global Depression Drugs: by Application USD Million (2023-2028)
  • Figure 42. Global Depression Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 43. South America Depression Drugs Share (%), by Country
  • Figure 44. Asia Pacific Depression Drugs Share (%), by Country
  • Figure 45. Europe Depression Drugs Share (%), by Country
  • Figure 46. MEA Depression Drugs Share (%), by Country
  • Figure 47. North America Depression Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbiVe Inc. (United States)
  • Janssen Pharmaceuticals (Belgium)
  • AstraZeneca (United Kingdom)
  • Eli Lilly and Company(United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Johnson & Johnson(United States)
  • H. Lundbeck AS (Denmark)
  • Merck & Co. Inc.(United States)
  • Pfizer Inc.(United States)
  • Sanofi (France)
  • Sun Pharmaceuticals Pvt. Ltd (India)
  • Dr. Reddy's Laboratories (India)
Select User Access Type

Key Highlights of Report


Dec 2023 222 Pages 70 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Depression Drugs Quantitative research analysis
Global Depression Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbiVe Inc. (United States), Janssen Pharmaceuticals (Belgium), AstraZeneca (United Kingdom), Eli Lilly and Company(United States), GlaxoSmithKline PLC (United Kingdom), Johnson & Johnson(United States), H. Lundbeck AS (Denmark), Merck & Co. Inc.(United States), Pfizer Inc.(United States), Sanofi (France), Sun Pharmaceuticals Pvt. Ltd (India) and Dr. Reddy's Laboratories (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The emergence of Novel Biologics" is seen as one of major influencing trends for Depression Drugs Market during projected period 2022-2028.
The Depression Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Depression Drugs Report?

Have a Query? Click Here

Other Related Reports

Ulcerative Colitis Comprehensive Study by Application (Hospital, Drugs Stores), Route of Administration (Oral, Injection), Disease level (Mild, Moderate, Severe), Ulcerative Colitis (Ulcerative proc...
$ 3650
Etoposide Comprehensive Study by Type (Etoposide for Injection, Etoposide for Oral Use), Application (Small Cell Lung Cancer, Testicular Cancer), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350
Soliris Drug Comprehensive Study by Type (Plasma Exchange, Plasma Infusion), Application (PNH, AHUS, HPP, GMG, Other), End-User (Pharmaceutical, Hospital, R&D labs, Others) Players and Region - Globa...
$ 3500
Sugar Sphere Comprehensive Study by Type (Micrometers, Standard spheres), Application (Tablets, Capsules), Form Type (Crystal, Granules) Players and Region - Global Market Outlook to 2029
$ 3500
Aloe Vera Extracts Comprehensive Study by Type (Gel Extracts, Whole Leaf Extracts, Powder, Others), Application (Food & Beverages, Pharmaceutical, Cosmetics, Others), Sales Channel (Online, Offline),...
$ 3800
Dry Eye Syndrome Drugs Comprehensive Study by Type (Lubricant Eye Drops (Preservative-free Drops, Oily Tear Eye Drops), Anti-inflammatory Drugs (Corticosteroid, Tetracyclines Oral), Autologous Serum ...
$ 3750